Published in Oncology Business Week, May 16th, 2004
Under the terms of the agreement, Eurand and the University of Urbino will collaborate to develop and evaluate the efficacy of the orally administered compound in the treatment of a broad range of cancers. The University of Urbino, which discovered the compound, will be responsible for its synthesis and preclinical evaluation.
Eurand will be responsible for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.